SOURCE: BioPharmetics, Inc.

May 11, 2006 08:31 ET

BioPharmetics, Inc. Signs Deal With Major West Coast Representative Group

NORTH HOLLYWOOD, CA -- (MARKET WIRE) -- May 11, 2006 -- BioPharmetics, Inc. (OTC: BPMT) announced the company has signed an agreement with Jay Halaby & Associates to sell the company's cosmetics products into beauty supply stores, nail stores, beauty redistributors, and ethnic stores. The company currently sells beauty products in 13 Western States, to include California, Nevada, Texas, and Washington.

"We're very excited to have Jay Halaby and Associates represent and sell our cosmetic products to the Western U.S. market. Their longstanding reputation as being one of the finest selling groups in the cosmetic industry will ensure the company continues to build upon sales and profitability as we move forward with our SB2 filing and eventual listing on OTCBB," stated Mr. Paul D. Lisenby, CEO of BioPharmetics, Inc. Mr. Lisenby further adds, "The continued support we offer through our $12 million dollar media campaign via NewsUSA will ensure that all customers Jay Halaby and Associates sell to will have the necessary product exposure in print and newspapers to drive traffic to their locations."

For more information about Jay Halaby and Associates, please visit their website at www.jayhalaby.com

For more information about all of BioPharmetics, Inc. products, please visit the website at www.biopharmetics.com

About BioPharmetics, Inc. (OTC: BPMT)

BioPharmetics, Inc. is a manufacturer and distributor of quality pharmaceutical, cosmetic, and anti-aging products. The company has three divisions: biotechnology, pharmaceuticals, and cosmetics/cosmeceuticals, working in unison to develop, manufacture, and distribute, high-quality products in the retail, wholesale, and professional markets. Brands currently offered include Toma™, Isseo™, Molo Africa™, Micha™, and Natural Angel™. BioPharmetics, Inc. also private labels many brands of cosmetics and cosmeceuticals for salons and retail stores as well as compounding specialized prescriptions for doctors nationwide.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.

Contact Information

  • Contact:
    FutureTechIR for BioPharmetics
    Investor Relations
    (817) 812-2105 or
    (727) 417-9338